Zealand boss must outperform Novo and Eli Lilly: "I'm not worried"

If Zealand Pharma gets its emergency treatment against low blood sugar approved by the FDA as expected, the company will face tough competition, but CEO Emmanuel Dulac believes he has the best product and is ready to prove it in trials.

Emmanuel Dulac, CEO of Zealand Pharma, is not scared of the competition from Novo Nordisk, Eli Lilly and Xeris. Photo: Zealand Pharma / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles